The independent source for health policy research, polling, and news.
261 - 280 of 752 Results
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Disability rights advocates and two individuals with disabilities sued Tuesday to overturn the state's physician-assisted death law, arguing it is unconstitutional, violates the Americans with Disabilities Act, and makes it too easy for people with terminal diseases whose deaths aren't imminent to kill themselves with a doctor's help.
The Supreme Court on April 21 ruled that the abortion pill mifepristone should remain widely available while the lower courts consider the issue, blocking earlier rulings that banned or restricted access to the drug. KFF Health News’ Julie Rovner joined NPR’s “Weekend All Things Considered” to discuss the complicated case.
The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.
Lisa French was told her surgery would cost $1,337. But the hospital sent her a bill for $229,000, then sued her. The case went all the way to the Colorado Supreme Court. The court’s ruling could have major implications for determining a “reasonable price” in health care.
The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
The American Medical Association ducked the abortion issue for years and now sees its members’ professional opinions second-guessed by lawmakers and judges. PhRMA is following the same playbook.
A federal judge’s recent ruling on the Affordable Care Act is by no means the final word. Even parsing its impact is complicated. Here are key issues to watch as the case works its way through the legal system.
A U.S. District Court ruling overturned the section of the Affordable Care Act that makes preventive health services — from colonoscopies to diabetes screenings and more — available at no cost to consumers.
A year after private equity-backed Noble Health shuttered two rural Missouri hospitals, a slew of lawsuits and state and federal investigations grind forward. Missouri Attorney General Andrew Bailey recently confirmed an “ongoing” investigation as former employees continue to go unpaid and cope with unpaid medical claims.
A U.S. District Court case is being widely followed because the judge’s decision could overturn the FDA’s approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.
A state law says giving false information to patients about covid-19 constitutes unprofessional conduct for which regulators can discipline doctors. Vaccine skeptics, including Robert F. Kennedy Jr., join civil liberties groups and others in arguing that it violates free speech.
Any day now a conservative federal judge in Texas could upend the national abortion debate by requiring the FDA to rescind its approval of mifepristone, a drug approved in the U.S. more than 20 years ago that is now used in more than half of abortions nationwide. Meanwhile, a controversial study on masks gets a clarification, although it may be too late to change the public impression of what it found. Alice Miranda Ollstein of Politico, Jessie Hellmann of CQ Roll Call, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
A Donald Trump-appointed federal judge agreed that even the possibility that the father’s daughters might access contraception without his permission violated the tenants of his Christian faith.
More than 10,000 dental patients have been fitted with an Anterior Growth Guidance Appliance, or AGGA, according to court records. But the unproven and unregulated device has not been evaluated by the FDA, according to a months-long joint investigation by KHN and CBS News.
More than 200 inmates killed themselves during eight years in which state prison officials failed to complete court-ordered suicide prevention safeguards. Inmates, the judge writes, have “waited far too long” for adequate mental health care.
A dental device called AGGA has been used on about 10,000 patients without FDA approval or proof that it works. In lawsuits, patients report irreparable harm. The AGGA’s inventor and manufacturer have denied all liability in court.
“What happens in Texas doesn't stay in Texas,” warns an abortion rights advocate bracing for a district judge’s ruling on whether the abortion pill mifepristone was properly authorized by the FDA. His decision could force the medication off the U.S. market.
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
After the BP Deepwater Horizon oil spill in 2020, Rodney Boblitt's job was to patrol a 14-mile stretch of coastline in the Florida Panhandle looking for signs of oil washing ashore. Today, the 54-year-old is among thousands of other cleanup workers who are experiencing health issues and suing BP. But proving their health conditions were caused by the oil has been challenging.
© 2026 KFF